An ideal molecular MRD marker should be exclusively present within the AML-defining clone, absent (or nearly absent) in the preleukemic state (such as CHIP or myelodysplastic syndrome [MDS]), correlate with therapeutic response, recur at disease relapse, and be technically feasible for molecular tracking. The gene discussed is STUB1; the disease is myelodysplastic syndrome.